Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Palese

Showing results (241-250 of 291) with videos related to

Pageof 30
Sort By:
Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.
Microbiology Spectrum|June 6, 2022
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in MiceIrene González-Domínguez, Jose Luis Martínez, Stefan Slamanig, et al.
Plos Pathogens|July 15, 2010
Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based librariesArun K Kashyap, John Steel, Adam Rubrum, et al.
Journal of Virology|January 9, 2015
Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responsesPeter H Goff, Tomoko Hayashi, Luis Martínez-Gil, et al.
Vaccines|December 22, 2020
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 VaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Nature Communications|November 3, 2018
Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse modelMark J Bailey, James Duehr, Harrison Dulin, et al.
ACS Infectious Diseases|May 19, 2015
A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin ProteinKris M White, Paul De Jesus, Zhong Chen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2020
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in MiceAlec W Freyn, Jamile Ramos da Silva, Victoria C Rosado, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2022
Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in miceIrene González-Domínguez, Jose Luis Martínez, Stefan Slamanig, et al.
Pageof 30

Showing results (241-250 of 291) with videos related to

Sort By:
Pageof 30
Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.
Microbiology Spectrum|June 6, 2022
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in MiceIrene González-Domínguez, Jose Luis Martínez, Stefan Slamanig, et al.
Plos Pathogens|July 15, 2010
Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based librariesArun K Kashyap, John Steel, Adam Rubrum, et al.
Journal of Virology|January 9, 2015
Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responsesPeter H Goff, Tomoko Hayashi, Luis Martínez-Gil, et al.
Vaccines|December 22, 2020
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 VaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Nature Communications|November 3, 2018
Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse modelMark J Bailey, James Duehr, Harrison Dulin, et al.
ACS Infectious Diseases|May 19, 2015
A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin ProteinKris M White, Paul De Jesus, Zhong Chen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2020
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in MiceAlec W Freyn, Jamile Ramos da Silva, Victoria C Rosado, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2022
Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in miceIrene González-Domínguez, Jose Luis Martínez, Stefan Slamanig, et al.
Pageof 30